Patent SG-11201810788Q-A (SG)
Title: Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto
Inventor: TRAN THUY-ANH
IPC: A61K31/4355
Filed: 2017-06-05
Abstract: OO N O C () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 December 2017 (14.12.2017) WIP0 I PCT omit VIII Hot o III OH olomonliolomo oimIE (10) International Publication Number WO 2017/214002 Al (51) International Patent Classification: CO7D 491/107(2006.01) A61P 9/00 (2006.01) A61K 31/4355 (2006.01) (21) International Application Number: PCT/US2017/035867 (22) International Filing Date: 05 June 2017 (05.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/346,293 06 June 2016 (06.06.2016) US (71) Applicant: ARENA PHARMACEUTICALS, INC. [US/US]; 6154 Nancy Ridge Drive, San Diego, California 92121 (US). (72) Inventors: TRAN, Thuy-Anh; 4833 Fairport Way, San Diego, California 92130 (US). DO, Quyen-Quyen; 10414 Rosedust Glen Drive, San Diego, California 92127 (US). ULLMAN, Brett; 3046 40th Street, San Diego, California 92105 (US). (74) Agent: SPRUCE, Lyle W. et al.; 6154 Nancy Ridge Drive, San Diego, California 92121 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO (57) : The present invention relates to compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the beta-3 adrenergic receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of a beta-3 adrenergic receptor-mediated disorder, such as, heart failure; cardiac performance in heart failure; mortality, reinfarction, and/or hospitalization in connection with heart failure; acute heart failure; acute decompensated heart failure; congestive heart failure; severe congestive heart failure; organ damage associated with heart failure (e.g., kidney damage or failure, heart valve problems, heart rhythm problems, and/or liver damage); heart failure due to left ventricular dysfunction; heart failure with normal ejection fraction; cardiovascular mortality following myocardial infarction; cardiovascular mortality in patients with left ventricular failure or left ventricular dysfunction; left ventricular failure; left ventricular dysfunction; class II heart failure using the New York Heart Association (NYHA) classification system; class III heart failure using the New York Heart Association (NYHA) classification system; class IV heart failure using the New York Heart Association (NYHA) classification system; LVEF < 40% by radionuclide ventriculography; LVEF <35% by echocardiography or ventricular contrast angiography; and conditions related thereto.